Johnson & Johnson

• Johnson and Johnson shares advanced following positive clinical trial data in electrophysiology. • Management raised full-year sales and adjusted earnings guidance amid solid third-quarter performance. • Institutional capital rotated into the healthcare leader, supported by strong dividend history.

• Moderna shares rose ahead of late-stage clinical trial results for intismeran autogene. • The companies are preparing regulatory submissions for United States Food and Drug Administration approval. • Moderna reported an annual revenue of $1.94 billion and a net loss.

• Eli Lilly's metabolic drugs and pipeline advancements drove strong investor sentiment. • The company reported $65.18B in annual revenue and $20.64B net profit. • Technical indicators show a buy signal with an RSI of 71.633.

• Merck shares rose due to positive oncology pipeline and Phase 3 trial data. • Strategic portfolio expansion and cardiovascular treatments alleviate patent expiration and revenue concerns. • Analysts maintain buy ratings with an average price target of $154.68.

• Novo Nordisk shares rebounded due to dip-buying and bullish options positioning. • Share repurchases and pipeline updates supported the company's valuation floor. • The stock exhibits neutral technical indicators with an annual revenue of $46.70B.

• Gilead partnered with Vir Biotechnology to develop next-generation oncology therapies. • Strong HIV franchise performance and bullish analyst coverage drove momentum. • The stock closed higher despite intraday volatility and profit-taking.